Discussion Since the introduction in renal transplant therapy, mT

Discussion Since the introduction in renal transplant therapy, mTOR inhibitors have been considered promising immunosuppressant due to their relatively low nephrotoxicity. The main mechan ism of action of these drugs is the inhibition BAY 73-4506 of cell signal ing through the PI3KAktmTOR pathway. mTOR is a large protein belonging Inhibitors,Modulators,Libraries to the phosphoino sitide kinase related kinase family. The carboxy terminal portion of mTOR contains both the kinase and the FKBP rapamycin binding domain. In mammals, mTOR associates with mammalian lethal with SEC13 protein 8, proline rich AKT substrate of 40 kDa and regulatory associated protein of mTOR to form the rapamycin sensitive mTOR complex 1. The mTORC1 activates protein synthesis through modulation of the 40S ribosomal protein S6 kinase and the translational initiation factor eIF 4E binding pro tein 1.

mTORC1 is acutely sensitive to inhibition by SirolimusEverolimus. Both drugs interact in mam malian cells with the immunophilin FKBP12, and the FKBP12 Inhibitors,Modulators,Libraries rapamycin Inhibitors,Modulators,Libraries complex then binds to the FRB do main in mTOR. On docking to the FRB domain, which is in close proximity to the catalytic site, the FKBP12 rapamycin complex allosterically inhibits mTORC1 kinase activity by an unknown mechanism. These biological effects confer to these drugs important immunosuppres sive and anti proliferative properties. Despite this potential, numerous published reports have described important EVE related adverse effects in organ transplant recipients. Particularly, in the last years, there have been described several interstitial pulmonary fibrosis events following mT OR I administration.

Although, the ethiopathoge netic mechanism associated to these pulmonary diseases is still not completely defined, the activation of a partial EMT in bronchial epithelial Inhibitors,Modulators,Libraries cells treated with mTOR I seems to have a pivotal role. These cells, in fact, showed higher protein expression of mesenchymal markers includ ing fibronectin and vimentin. Therefore, to evaluate whether EVE Inhibitors,Modulators,Libraries treatment was able to induce EMT in human proximal tubular cells, we measured, by RT PCR, changes in expression level of four genes encoding for well known EMT markers in wild type and HPSE silenced HK2 cells incubated for 6 hours with 10, 100, 200 and 500 nM EVE. We chose to test in vitro high EVE concentrations, because corresponding to dosage frequently used in chemothera peutic protocols.

Our results demonstrated that WT HK 2 cells cultured with high concentrations of EVE exhibited an up regulation of all four EMT markers both at gene and protein level. Additionally, these dosages in duced the increase of MMP 9 enzymatic activity and a sig nificant cellular migration in the same cell lines. On the other side, low dose of EVE, usually research use only used for organ transplantation, was unable to induce EMT in WT cells. This is in line with several published papers reporting potential anti fibrotic kidney properties of both mTOR I.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>